Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

25). 1 "Real-world analyses such ... 1 Revised MACE-5 occurred in 88 (0.94%) of the 9,321 patients in the semaglutide 2.4 mg group and 288 (1.54%) of 18,642 patients in the non-user group.

1,5 In this prespecified secondary analysis of the SELECT trial, semaglutide 2.4 mg reduced total events (first and subsequent) by 22% (MR 0.78 ... 195 Countries over 25 Years.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Out of 1,363 screened candidates, 792 participants were selected and randomized 1:1 to subcutaneous semaglutide (1.0 mg once weekly) or placebo for 52 weeks. This cohort was 25% women and had a median ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...